Literature DB >> 1689784

Comparison of the nuclear 5 alpha-reduction of testosterone and androstenedione in human prostatic carcinoma and benign prostatic hyperplasia.

R W Hudson1, D Wherrett.   

Abstract

The nuclear conversion of testosterone (T) to dihydrotestosterone (DHT) and androstenedione (delta 4A) to androstanedione (5 alpha-Adione) was compared in the separated stromal and epithelial fractions of hyperplastic (n = 6) and malignant (n = 3) prostatic tissues. Assay conditions were linear with respect to time and protein concentration and were optimal for NADPH concentration. The apparent Km values for the stromal enzymes were 0.2 and 0.02 microM for hyperplasia and carcinoma, respectively, using T as substrate. The apparent Km values, using delta 4A as substrate, were 0.03 and 0.02 microM, respectively. Apparent Vmax values for the stromal formation of DHT were 16.5 +/- 5.4 and 1.97 +/- 0.45 pmol/mg protein/30 min incubation, respectively, for the hyperplastic and malignant tissues. The apparent Vmax values for the formation of 5 alpha-Adione were 2.8 +/- 1.3 and 6.5 +/- 1.2 pmol/mg/protein/30 min incubation. The apparent Km values for the epithelial enzyme, for hyperplastic and malignant tissue were 0.04 and 0.04 microM, for T, and 0.05 and 0.03 microM for delta 4A. The respective apparent Vmax values were 4.6 +/- 0.93 and 0.65 +/- 0.07 for DHT and 2.0 +/- 0.86 and 6.4 +/- 0.45 pmol/mg protein/30 min incubation for 5 alpha-Adione. delta 4A was a competitive inhibitor of T 5 alpha-reduction. These results provide further evidence that different rates of 5 alpha-reduction at least partially explain the differences in androgen levels seen in the hyperplastic and the malignant prostate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689784     DOI: 10.1016/0022-4731(90)90279-2

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  3 in total

1.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

Authors:  A E Thigpen; R I Silver; J M Guileyardo; M L Casey; J D McConnell; D W Russell
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

2.  Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.

Authors:  Tomoe Fujita; Yoshiaki Matsumoto; Toshimi Kimura; Shinichi Yokota; Mika Sawada; Masataka Majima; Yoshio Ohtani; Yuji Kumagai
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

3.  Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity.

Authors:  M F Palin; M Faguy; J G LeHoux; G Pelletier
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.